ω-3 Fatty Acid Synergized Novel Nanoemulsifying System for Rosuvastatin Delivery: In Vitro and In Vivo Evaluation
- 170 Downloads
The present study was undertaken to improve rosuvastatin (RSV) bioavailability and pharmacological response through formation of SNES using Perilla frutescens oil as lipid carrier. The composition of oil was estimated by fatty acid methyl ester (FAME) analysis using gas chromatography. Solubility of RSV in Perilla frutescens oil and Cremophor EL was 25.0 ± 3.0 and 60.0 ± 5.0 mg/mL, respectively. Later, nanophasic maps and a central composite design were employed to determine the maximum nanoemulsion region and further optimize SNES in this study. Finally, the optimized formulation was evaluated in vitro and in vivo. FAME analysis revealed that PUFA content was 70.3% of total fatty acid. Optimized SNES formulation demonstrated particle size of 17.90 nm, dissolution 98.80%, cloud point 45°C, emulsification time 2 min, and viscosity 241.41 ± 5.52 cP. The hypolipidemic property of SNES was further explored using Triton X-100-induced hyperlipidemic rat model, and there were reductions of serum cholesterol, triglyceride, and LDL and VLDL levels in the SNES-treated group as compared to the toxic control. Pharmacokinetic study of SNES revealed significantly higher C max (60.13 ± 25.43 ng/mL) and AUC0–∞ (6195 ± 42.38 ng h/mL) vis-à-vis marketed tablet (284.80 ± 13.44 ng/mL, 3131.72 ± 51.93 ng h/mL, respectively). RSV was successfully incorporated into ω-3 fatty acid-based SNES with improved pharmacokinetic parameters (~ 2-fold improved bioavailability) and better hypolipidemic properties, owing to the synergistic effects of hepatic lipid regulation itself. The results clearly explicated that ω-3 fatty acid-based SNES effectively enhanced bioavailability and pharmacological responses of RSV, suggesting that these formulations may be useful as alternative for hyperlipidemia treatment in future drug design perspective.
KEY WORDSrosuvustatin self-nanoemulsifying system ω-3 fatty acid hypolipidemic action Perilla frutescens oil
The authors acknowledge the kind support of M/s IPCA Pharmaceuticals Pvt. Ltd., Mumbai and M/s BASF, Germany, for providing the ex gratis samples. The authors also acknowledge the SAIF Department, Babasaheb Bhimrao Ambedkar University for providing some evaluation facilities for this research work.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
- 1.Benito-Gallo P, Marlow M, Zann V, Scholes P, Gershkovich P. Linking in vitro lipolysis and microsomal metabolism for the quantitative prediction of oral bioavailability of BCS II drugs administered in lipidic formulations. Mol Pharm. 2016;13(10):3526–40. https://doi.org/10.1021/acs.molpharmaceut.6b00597.CrossRefPubMedGoogle Scholar
- 2.Bandyopadhyay S, Beg S, Katare OP, Sharma G, Singh B. QbD-oriented development of self-nanoemulsifying drug delivery systems (SNEDDS) of valsartan with improved biopharmaceutical performance. Curr Drug Deliv. 2015;12(5):544–63. https://doi.org/10.2174/1567201812666150227125639.CrossRefPubMedGoogle Scholar
- 5.Elgart A, Cherniakov I, Aldouby Y, Domb AJ, Hoffman A. Improved oral bioavailability of BCS class 2 compounds by self nano-emulsifying drug delivery systems (SNEDDS): the underlying mechanisms for amiodarone and talinolol. Pharm Res. 2013;30(12):3029–44. https://doi.org/10.1007/s11095-013-1063-y.CrossRefPubMedGoogle Scholar
- 6.Singh B, Beg S, Khurana RK, Sandhu PS, Kaur R, Katare OP. Recent advances in self-emulsifying drug delivery systems (SEDDS). Crit Rev Ther Drug Carrier Syst. 2014;31(2):121–85. https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2014008502.CrossRefPubMedGoogle Scholar
- 7.Beg S, Katare OP, Singh B. Formulation by design approach for development of ultrafine self-nanoemulsifying systems of rosuvastatin calcium containing long-chain lipophiles for hyperlipidemia management. Colloids Surf B Biointerfaces. 2017;159:869–79. https://doi.org/10.1016/j.colsurfb.2017.08.050.CrossRefPubMedGoogle Scholar
- 9.Martin PD, Warwick MJ, Dane AL, Hill SJ, Giles PB, Phillips PJ, et al. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin Ther. 2003;25(11):2822–35. https://doi.org/10.1016/S0149-2918(03)80336-3.
- 11.Singh M, Kanoujia J, Singh P, Tripathi CB, Arya M, Parashar P, et al. Development of an α-linolenic acid containing soft nanocarrier for oral delivery: in vitro and in vivo evaluation. RSC Adv. 2016;6(81):77590–602. https://doi.org/10.1039/C6RA15166C.
- 13.Yu H, Qiu JF, Ma LJ, Hu YJ, Li P, Wan JB. Phytochemical and phytopharmacological review of Perilla frutescens L. (Labiatae), a traditional edible-medicinal herb in China. Food Chem Toxicol. 2016;S0278-6915(16):30439–2.Google Scholar
- 16.Scorletti E, Byrne CD. Omega-3 fatty acids, hepatic lipid metabolism, and nonalcoholic fatty liver disease. Annu Rev Nutr. 2013;33(1):231–48. https://doi.org/10.1146/annurev-nutr-071812-161230.CrossRefPubMedGoogle Scholar
- 23.Singh M, Ganggwar N, Parashar P, Tripathi CB, Arya M, Saraf SA, et al. Topical delivery of fluconazole via microemulsion incorporated hydrogel for the management of fungal dermatophytosis. Curr Drug Ther. 2016;11(2):129–41. https://doi.org/10.2174/1574885511666160822143148.
- 29.Singh B, Bandopadhyay S, Kapil R, Singh R, Katare OP. Self-emulsifying drug delivery systems (SEDDS): formulation development, characterization, and applications. Crit Rev Ther Drug Carrier Syst. 2009;26(5):427–521. https://doi.org/10.1615/CritRevTherDrugCarrierSyst.v26.i5.10.CrossRefPubMedGoogle Scholar
- 32.Weintraub MS, Zechner R, Brown A, Eisenberg S, Breslow JL. Dietary polyunsaturated fats of the W-6 and W-3 series reduce postprandial lipoprotein levels. Chronic and acute effects of fat saturation on postprandial lipoprotein metabolism. J Clin Invest. 1988;82(6):1884–93. https://doi.org/10.1172/JCI113806.CrossRefPubMedCentralPubMedGoogle Scholar
- 37.Gao F, Zhang Z, Bu H, Huang Y, Gao Z, Shen J, et al. Nanoemulsion improves the oral absorption of candesartan cilexetil in rats: performance and mechanism. J Control Release. 2011;149(2):168–74. https://doi.org/10.1016/j.jconrel.2010.10.013.
- 39.Singh M, Kanoujia J, Singh P, Tripathi CB, Arya M, Parashar P, et al. Development of an a-linolenic acid containing soft nanocarrier for oral delivery part II: buccoadhesive gel. RSC Adv. 2016;6(103):101602–12. https://doi.org/10.1039/C6RA20896G.